This invention relates to polynucleotides comprising optimized SUMF1 open reading frame (ORF) sequences, vectors comprising the same, and methods of using the same for deliver) of the ORF to a cell or a subject and to treat disorders associated with aberrant expression of a SUMF1 gene or aberrant activity of a SUMF1 gene product in the subject, such as SUMF1 disease.

Provided are HIV-1 fusion polypeptides, polynucleotides encoding such fusion polypeptides, vectors expressing such fusion polypeptides for use in eliciting an immune response against HIV-1; pharmaceutical and immunogenic compositions and kits comprising such fusion polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HIV-1. Further provided are methods for design of antiviral vaccines, including vaccines to elicit an immune response against HIV-1.

Gene therapy vectors can include a cytomegalovirus vector encoding one or more therapeutic donor genes. These vectors can be used in exemplary gene therapy methods for maintaining or improving one or more aspects of a recipient's physiological wellness and/or longevity. The recombinant viral vector can be administered or received intranasally or as an injectable therapeutic (singly or as a serial set of administrations) to beneficially cause one or more of the following salubrious effects in the patient: increased longevity, inhibited muscle degeneration, increases mitochondrial health, prevention of age-related hair loss, and/or increased blood glucose tolerance.

The present disclosure relates to methods to generate an immune response for the treatment or prevention of hepatitis B virus infection. This disclosure also relates to methods to generate MHC-E and/or MHC-II restricted CD8.sup.+ T cells for the treatment or prevention of hepatitis B virus infection.

The present invention provides compositions and methods for inducing immune responses in subjects using HV-based vectors that can be grown in single celled organisms and administered in their nucleic acid form.

The present disclosure relates to AAV vectors, compositions, and methods related to converting glial cells to neurons by the use of ISL1 and LHX3 coding sequences in an AAV vector.

Disclosed herein are cytomegalovirus vectors encoding fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.

The present disclosure relates to recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens, which may be used, for example, for the treatment or prevention of infectious disease or cancer. The recombinant RhCMV or HCMV vectors elicit and maintain high level cellular immune responses specific for the heterologous antigen while including deletions in one or more genes essential or augmenting for CMV replication, dissemination or spread.

Human cytomegalovirus vectors comprising heterologous antigens are disclosed. The vectors derived from the TR strain, are ganciclovir sensitive, include active US2, US3, US6, US7 and UL131A genes, and have a deleterious or inactivating mutation in the UL82 gene preventing the expression of pp71.

The present invention provides compositions and methods for treating a cancer using liposomes. Collectively, the liposomes contain a protein and a vector encoded for a gene corresponding to the protein. The amount of the protein and the vector a plurality of liposome is sufficiently effective to treat cancer cells. At least some of the liposomes can contain an antibody that recognizes, and thereby targets, a protein expressed on the cancer cell.